CD8A and COVID-19: These results suggest that vaccine approaches that elicit antiviral SARS-CoV-2-specific CD4+ and CD8+ T cells in coordination with neutralizing antibodies will generate protective immunity that most closely analogous to the coordinated adaptive antiviral immune response seen in most cases of COVID-19 following natural SARS-CoV-2 infection.